Silence Therapeutics Discussion Board http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion http://www.iii.co.uk/icons/logos/uk_logo.gif http://www.iii.co.uk tag:iii.co.uk,2003:tst.9641570
if i (or anyone) got £110k lying around they will be lying around in a beach in the bahamas not responding to this message :-) By notrichyet ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9641570&action=detail Tue, 15 May 2012 08:54:00 GMT notrichyet tag:iii.co.uk,2003:tst.9640451 I bought astra zeneca, bowleven and yell last month based on charts and all are going down big time.
Analyst saying this year is bad for shares so maybe its time to buy silver and other commodities.
Currency i dont understand at all.
If FTSE hits below 4000 then time to buy stocks. in 2008 barclays went to 50p.
By the way if you got 110k lying around you can buy to lett and earn 7% income By faiz23 ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9640451&action=detail Mon, 14 May 2012 21:36:00 GMT faiz23 tag:iii.co.uk,2003:tst.9637603
Sympathize alot with your losses ( I know all about it with SLN), as I'm sure many others do so too, unfortunately someone needs to raise the alarm against this flawed company and the "rampers" in this noticeboard aren't doing anyone a favor.

Regarding other investment ideas, tough call really, as stocks seem overpriced in my view given the doom & gloom in the economy, but as a general advice try to think about "making money" as opposed to "recovering losses" as the psychology leads to different trades /results.

in case you're into currencies I am long £ / Euro for sometime, and its the only thing I see positive for the time being , but you might need a lower entry point if you fancy this trade.

Good luck By notrichyet ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9637603&action=detail Mon, 14 May 2012 10:41:00 GMT notrichyet tag:iii.co.uk,2003:tst.9624227 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9624227&action=detail Wed, 09 May 2012 18:34:00 GMT Valueseeker tag:iii.co.uk,2003:tst.9623590
The "potential" royalities have been in the range of $200M since 2007 ( 5 years ago)

Hardly any were achieved of course as the company failed to deliver against it, and nothing changes the real story with this meaningless statement.

And to make it more cheap the company's website highlights the drug's market size in $billions . It's like a newsagent grocery displaying the balance sheet of Tesco in their website !

If you don't believe this company is going into administration just compare its 2 year chart with clinton cards ( ticker cc.) which went bust today.

There's a reason for everything, only the blind fail to see it.

DYR By notrichyet ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9623590&action=detail Wed, 09 May 2012 15:45:00 GMT notrichyet tag:iii.co.uk,2003:tst.9604686
May 3, 2012, 2:00 a.m. EDT

Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication
LONDON, May 3, 2012 /PRNewswire via COMTEX/ -- Silence Therapeutics Plc (aim:SLN), a leading international RNAi therapeutics company, notes that its partner, Quark Pharmaceuticals, has announced it has amended its existing exclusive Licensing Agreement with Pfizer. This amendment will enable Quark to perform a Phase 2a clinical study to assess the effect of PF-655 in a new indication, looking at visual function in patients with moderate and advanced Open-Angle Glaucoma (OAG). PF-655 incorporates Silence's AtuRNAi technology and was sub-licensed to Pfizer by Quark in 2006, and on which Silence is entitled to receive a share of milestones and royalties that may be earned by Quark in the future on this compound.

The OAG study will be conducted in parallel with a Phase 2b study of PF-655 in diabetic macular oedema.

Silence has previously announced that it stood to receive up to $95m from Quark in relation to its licensing agreement with Pfizer. As a result of this amendment to the Quark/Pfizer license, Silence anticipates its share of these payments could now reach $120m. Silence has previously announced the receipt of $6m from Quark in relation to this licence.

Commenting on the announcement, Tony Sedgwick, Chief Executive Officer of Silence, said: "This is an exciting development for Silence. This will create a fifth external clinical program using Silence's IP and AtuRNAi, which is funded and managed by one of our partners. This will increase the potential share of milestones and royalties that Silence can earn under its agreement with Quark and is a further validation of the Silence technology."

The announcement issued by Quark Pharmaceuticals is shown below:

Quark Pharmaceuticals Announces Phase 2a Study of PF--04523655 (PF-655) in Patients With Moderate and Advanced Open-Angle Glaucoma (OAG)

FREMONT, Calif., May 1, 2012 - Quark Pharmaceuticals, Inc., today announced that Quark and Pfizer have amended their existing exclusive Licensing Agreement in order to enable Quark to perform a Phase 2a clinical study to assess the effect of PF-655 on visual function in patients with moderate and advanced Open-Angle Glaucoma (OAG). This study will be conducted in parallel with an ongoing Phase 2b study (QRK202) in diabetic macular edema (DME). The OAG study will evaluate the potential of PF-655 to enhance visual function in glaucoma. Under the amended agreement, should Pfizer assume development and potential commercialization of PF-655 in either or both indications following review of the Phase 2a PF-655 data, Quark will receive option exercise payments and be will eligible to receive development and regulatory milestones specific to each indication, as well as sales milestones and royalties. Quark may be eligible to receive additional total payments of up to approximately $165 million associated with development and approval of PF-655 for OAG.

Preclinical studies of PF-655 conducted by Quark suggest the potential of the compound as a neuroprotective and potentially neuroenhancing agent in diseases such as OAG, by preventing optic neural cell apoptosis and stimulating optic neural cell regeneration. In addition, in a Phase 2a study in patients with DME (Pfizer DEGAS study #B0451004), repeated injections of PF-655 showed a dose-dependent increase in visual acuity independent of changes in retinal thickness. The beneficial effects of PF-655 on visual function may potentially be due to effects on retinal cells themselves, rather than on vascular permeability.

The OAG study will be a Phase 2a, multi-center, double-masked, randomized, repeat dose, safety, tolerability and efficacy study in up to 108 patients with moderate and advanced OAG. In addition, Quark is currently conducting a Phase 2b st By M33 Investor ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9604686&action=detail Thu, 03 May 2012 12:33:00 GMT M33 Investor tag:iii.co.uk,2003:tst.9604675
Silence previously said it would receive up to $95 million from Quark in relation to its agreement with Pfizer. It now anticipates its share of these payments could reach $120 million.

The amendment to the licensing agreement between Quark and Pfizer will enable Quark to perform a phase 2a clinical study to assess the effect of PF-655, which incorporates Silence's AtuRNAi technology, in a new indication, looking at visual function in patients with moderate and advanced open-angle glaucoma, an eye disease, Silence said.

http://www.marketwatch.com/story/silence-therapeutics-to-benefit-from-pfizer-change-2012-05-03 By M33 Investor ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9604675&action=detail Thu, 03 May 2012 12:32:00 GMT M33 Investor tag:iii.co.uk,2003:tst.9595136
Thursday 10th May
Chesterfield Mayfair Hotel
Starts at 6pm

http://www.proactiveinvestors.co.uk/register/event_details/147 By Ribz ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9595136&action=detail Tue, 01 May 2012 10:05:00 GMT Ribz tag:iii.co.uk,2003:tst.9586709
Save your pennies while you can

These discussion boards are full of angry shareholders who go about how directors should be sued / brought to account etc. etc. after a company collapses with no previous warning.

Well, you have been warned.


DYR
By notrichyet ]]> http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9586709&action=detail Fri, 27 Apr 2012 19:01:00 GMT notrichyet tag:iii.co.uk,2003:tst.9564437 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9564437&action=detail Sun, 22 Apr 2012 11:28:00 GMT The Cambodian tag:iii.co.uk,2003:tst.9547565 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9547565&action=detail Wed, 18 Apr 2012 07:33:00 GMT ozzywhiteman tag:iii.co.uk,2003:tst.9547087 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9547087&action=detail Tue, 17 Apr 2012 22:55:00 GMT Billthebank tag:iii.co.uk,2003:tst.9544532 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9544532&action=detail Tue, 17 Apr 2012 11:50:00 GMT ozzywhiteman tag:iii.co.uk,2003:tst.9544333 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9544333&action=detail Tue, 17 Apr 2012 11:09:00 GMT Valueseeker tag:iii.co.uk,2003:tst.9543649 http://www.iii.co.uk/investment/detail?code=cotn:SLN.L&display=discussion&id=9543649&action=detail Tue, 17 Apr 2012 08:25:00 GMT ozzywhiteman